Paper20175033
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R and 1 other. Semin Liver Dis, 2010. Cited by 3,769 papers, by iCite.
Cite this record
ConductScience Library. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Papers, record 20175033. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20175033
- Disease
- hepatocellular carcinoma478 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Fluorodeoxyglucose F18 | Major topic |
| Liver Neoplasms | Major topic |
| Practice Guidelines as Topic | Major topic |
| Clinical Trials as Topic | |
| Diagnostic Imaging | |
| Drug Delivery Systems | |
| Humans | |
| Magnetic Resonance Imaging | |
| Neoplasm Staging | |
| Outcome Assessment, Health Care | |
| Positron-Emission Tomography | |
| Prognosis | |
| Radiopharmaceuticals | |
| Tomography, X-Ray Computed | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 DK076986 | NIDDK NIH HHS | United States | R01DK076986 | PubMed and NIH |
| 1R01DK076986-01 | NIDDK NIH HHS | United States | R01DK076986 | PubMed and NIH |
Source NIH RePORTER
Trials12
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01387503 | Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging | Background | ClinicalTrials.gov | |
| NCT02311205 | Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) | Background | ClinicalTrials.gov | |
| NCT02630108 | TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma | Results | ClinicalTrials.gov | |
| NCT02729506 | Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma | Results | ClinicalTrials.gov | |
| NCT03248375 | Impact of Y90 Radiation Segmentectomy on HCC | Background | ClinicalTrials.gov | |
| NCT04048317 | Effectiveness of Drug Eluting TACE in Primary HCC | Background | ClinicalTrials.gov | |
| NCT04803019 | Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma | Background | ClinicalTrials.gov | |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | Background | ClinicalTrials.gov | |
| NCT05185505 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Background | ClinicalTrials.gov | |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | Background | ClinicalTrials.gov | |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Background | ClinicalTrials.gov | |
| NCT06642220 | Ablative Radioembolization of Renal Cell Carcinoma Trial | Background | ClinicalTrials.gov |
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 2 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 3 | 7459811 | Reporting results of cancer treatment. | Cancer | 1981 | https://conductscience.org/library/papers/7459811 | PubMed |
| 4 | 12540794 | Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. | Hepatology | 2003 | https://conductscience.org/library/papers/12540794 | PubMed |
| 5 | 19095437 | Individual patient data analysis to assess modifications to the RECIST criteria. | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19095437 | PubMed |
| 6 | 16298014 | Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. | J Hepatol | 2006 | https://conductscience.org/library/papers/16298014 | PubMed |
| 7 | 19117042 | Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? | Cancer | 2009 | https://conductscience.org/library/papers/19117042 | PubMed |
| 8 | 10655437 | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10655437 | PubMed |
| 9 | 18477802 | Design and endpoints of clinical trials in hepatocellular carcinoma. | J Natl Cancer Inst | 2008 | https://conductscience.org/library/papers/18477802 | PubMed |
| 10 | 16250051 | Management of hepatocellular carcinoma. | Hepatology | 2005 | https://conductscience.org/library/papers/16250051 | PubMed |
| 11 | 11592607 | Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. | J Hepatol | 2001 | https://conductscience.org/library/papers/11592607 | PubMed |
| 12 | 14667750 | Hepatocellular carcinoma. | Lancet | 2003 | https://conductscience.org/library/papers/14667750 | PubMed |
| 13 | 14512891 | MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. | Hepatology | 2003 | https://conductscience.org/library/papers/14512891 | PubMed |
Cited by2,373
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,769 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984496 | Muscle strength and muscle mass phenotypes and survival in unresectable hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy-based combination therapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42984496 | PubMed |
| 42982861 | FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study. | Nat Commun | 2026 | https://conductscience.org/library/papers/42982861 | PubMed |
| 42973518 | Early discordance between alpha-fetoprotein response and albumin-bilirubin deterioration refines response assessment in unresectable hepatocellular carcinoma receiving first-line immune-combination therapy: a real-world landmark cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42973518 | PubMed |
| 42968863 | Efficacy and Safety of Sequential Radiotherapy and Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Single-Center PSM Retrospective Cohort Study. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42968863 | PubMed |
| 42967182 | Conversion Surgery After HAIC-Based Combination Therapy with Targeted Therapy and Immune Checkpoint Inhibitors for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42967182 | PubMed |
| 42967027 | Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42967027 | PubMed |
| 42960031 | Sequential surgery after conversion therapy for advanced hepatocellular carcinoma: Evidence, controversies, and perspectives. | ILIVER | 2026 | https://conductscience.org/library/papers/42960031 | PubMed |
| 42953006 | CT habitat and peritumoral radiomics for predicting progression after repeat TACE in hepatocellular carcinoma: a multicenter study. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42953006 | PubMed |
| 42948561 | von Willebrand Factor and ADAMTS13 Predict Therapeutic Efficacy and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Atezolizumab-Bevacizumab. | JGH Open | 2026 | https://conductscience.org/library/papers/42948561 | PubMed |
| 42938898 | Baseline Host Biomarkers and Six-Month Sustained Drug-Free Status After Atezolizumab-Bevacizumab for Hepatocellular Carcinoma: Exploratory Clinical Stratification Using PAN-DF Score. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938898 | PubMed |
| 42938852 | BCIW-Net: Boundary-Conditioned Adaptive CT Windowing for Hepatocellular Carcinoma Segmentation. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938852 | PubMed |
| 42938169 | Treatment-Stratified Immune-Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42938169 | PubMed |
| 42936717 | Salvage Yttrium-90 Transarterial Radioembolization Combined with Second-Line Molecular Targeted Agents and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Progressing After TACE-Based Combination Therapy: A Single-Center Real-World Study. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42936717 | PubMed |
| 42924150 | Drug-eluting bead transarterial chemoembolization with immunotherapy and targeted therapy for advanced clear cell renal cell carcinoma: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42924150 | PubMed |
| 42921173 | The Efficacy and Safety of Combined Locoregional and Systemic Therapy versus Systemic Therapy Alone in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: A Multicenter Real-World Retrospective Cohort Study. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42921173 | PubMed |
| 42910203 | Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42910203 | PubMed |
| 42909267 | Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42909267 | PubMed |
| 42908779 | Low CT-derived vertebral attenuation as a prognostic factor in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. | Front Oncol | 2026 | https://conductscience.org/library/papers/42908779 | PubMed |
| 42908554 | LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab. | Front Oncol | 2026 | https://conductscience.org/library/papers/42908554 | PubMed |
| 42895551 | Sequential transarterial radioembolization and atezolizumab plus bevacizumab improves survival in advanced hepatocellular carcinoma. | Eur Radiol | 2026 | https://conductscience.org/library/papers/42895551 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ETHIODIZED OIL | CHEMBL1201458 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201458 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20175033
GET https://conductscience.org/api/papers/v1/20175033/cited_by?page=2